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Abstract Internalization of membrane proteins has been
studied for more than three decades without solving all the
underlying mechanisms. Our knowledge of the clathrin-coated
endocytosis is su⁄cient to understand the basic principles. How-
ever, more detailed insight is required to recognize why di¡erent
proteins enter clathrin-coated pits with di¡erent rates and a⁄n-
ities. In addition to clathrin coat components, several adapter
systems and even more accessory proteins have been described
to preselect membrane proteins before they can enter cells. Re-
cent experimental data have identi¢ed the ubiquitin^proteasome
system as a regulatory system both in endocytic and lysosomal
membrane tra⁄c. This system is well-known for its basic regu-
latory function in protein degradation, and controls a magnitude
of key events. In this review, we will discuss the complexity and
implications of this mechanism for membrane tra⁄cking with
emphasis on the growth hormone receptor. ' 2002 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. The ubiquitin^proteasome system
Initially, the ATP-dependent conjugation of the 76 amino-
acid-long ubiquitin to abnormal or misfolded cytosolic pro-
teins was found to mediate their degradation (review in [1]).
At present, however, ubiquitylation is considered to be in-
volved in a wide variety of cellular processes that do not
only involve degradation, but play a role in regulation of
cell cycle, di¡erentiation and development, stress response,
DNA repair, gene transcription, immune response, degrada-
tion of misfolded proteins in the endoplasmic reticulum (ER)
(ER-associated degradation or ERAD), modulation of cell
surface receptors and ion channels, muscle wasting, and apo-
ptosis. Considering the involvement in so many processes it is
not surprising that aberrations in the ubiquitylation pathway
are implicated in many pathological disorders.
Ubiquitin conjugation to substrate proteins requires the
successive action of several enzymes [1]. First, in an ATP-de-
pendent step, the ubiquitin-activating enzyme (E1) forms a
high-energy thiol-ester between the active site cysteine residue
and the C-terminal glycine residue of ubiquitin. Subsequently,
a ubiquitin-conjugating enzyme (E2) accepts the activated
ubiquitin from the E1 to form an E2-SVubiquitin intermedi-
ate involving the E2 active-site cysteine. The ¢nal conjugation
of the ubiquitin molecule to the substrate can be mediated
directly by E2, but frequently requires an ubiquitin protein
ligase (E3), in addition. The ubiquitin moiety is conjugated
via its C-terminal glycine to the O-amino-group of a lysine
residue or in some cases the K-amino-group of the N-terminal
residue of the substrate [2]. A substrate can be modi¢ed with a
single ubiquitin moiety (monoubiquitylation) but since ubiq-
uitin itself contains seven lysine residues, repetition of the
conjugation reaction can also result in the formation of poly-
ubiquitin chains. The fate of a polyubiquitylated protein de-
pends on the length and linkage type of the ubiquitin chain
[3]. In general, substrates with chains of four or more ubiq-
uitin molecules linked via lysine 29 or 48 are e⁄ciently tar-
geted for degradation by a large multimeric cytosolic protease,
the 26S proteasome. Unlike the substrate, the ubiquitin mol-
ecules are not degraded but recycled for new conjugation re-
actions. Rather than proteasome-targeting signals, lysine 63-
linked polyubiquitin chains might be involved in regulation of
endocytosis of membrane channel proteins [4], DNA repair
[5], and kinase activation [6]. Analogous to protein phospha-
tases, deubiquitylating enzymes (DUBs) play an important
role in the timing and intensity of ubiquitylation-controlled
events [7^9] and are required for ubiquitin homeostasis [10].
In every instance, class and variety of the E3 ligase mainly
determines the speci¢city of the ubiquitin system (Fig. 1). The
E3 enzymes are divided into three categories: HECT domain,
RING ¢nger and U-box E3s. HECT domain E3s contain a
conserved cysteine residue required for thiol-ester linkage of
ubiquitin within a 350 amino-acid region with homology to
the E6-AP C-terminus [11,12]. Most HECT domain E3s con-
tain WW domains that interact with proline-rich, phosphory-
lated tyrosine (PY) motifs of the substrate and a N-terminal
C2 domain that mediates translocation to the plasma mem-
brane upon intracellular Ca2þ increase [4]. A well-studied ex-
ample of HECT domain E3s is Nedd4, which mediates the
ubiquitylation and endocytosis of the amiloride-sensitive so-
dium channel (ENaC). ENaC is apically located and ex-
pressed primarily in the polarized epithelia of the distal neph-
ron, lung, distal colon, and other organs. It is composed of
three related subunits, K, L, and Q, arranged in a stoichiometry
of 2K :1L :1Q. Mutation of the PY motifs of ENaC, as seen in
Liddle’s syndrome patients, prevents ENaC ubiquitylation
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and causes hypertension due to the prolonged activation of
the sodium channels [13,14]. The yeast homolog of Nedd4,
Npi1/Rsp5, is involved in regulating internalization of several
transporters and plasma membrane receptors [4]. In addition,
Rsp5 induces the release of two transcription factors, Spt23
and Mga2, by facilitating the ubiquitin- and proteasome-de-
pendent cleavage of their membrane-anchored ER precursor
proteins (Fig. 1) [15]. Under certain nutritional conditions,
Rsp5 (together with Bul1) was found to regulate the sorting
of the general amino acid permease, Gap1, from the trans-
Golgi network (TGN) to the vacuole [16]. Nedd4 is also in-
volved in the budding of some viruses. Both the VP40 protein
of Ebola virus and Gag and M proteins of speci¢c retrovi-
ruses and rhabdoviruses, respectively, possess a Nedd4 inter-
acting PY motif [17^19]. Together, Nedd4/Rsp5 is an exqui-
site example of a single E3 that regulates the activity of
di¡erent proteins at distinct cellular locations.
The second group of E3 ligases comprises the RING (really
interesting new gene) E3s. These ligases contain a structural
element, the RING ¢nger, which is de¢ned by a pattern of
conserved cysteine and histidine residues that bind two zinc
ions [20]. In complex RING E3s, the RING domain is re-
quired for the recruitment of E2 enzymes, while single-subunit
RING E3s contain both the E2 and substrate binding sites on
the same molecule. Examples of the latter are c-Cbl, involved
in ubiquitylation of cell surface growth factor receptors [21],
Mdm2 that ubiquitylates the tumor suppressor protein p53
[22], and the inhibitors of apoptosis (IAPs)[23]. The multisub-
unit E3 complexes comprise the anaphase promoting complex
or cyclosome involved in the degradation of cell cycle regu-
lators [24], the Skp1/cullin1/F-box (SCF) complex that medi-
ates the degradation of many signal- and cell cycle-induced
phosphorylated proteins [25], and the von Hippel-Lindau/
elongin C/elongin B/cullin2 complex, a regulator of hypoxia-
inducible transcription factor 1K [26]. The SCFLTrCP E3 in-
teracts via the WD40 motif with Hiv-1 Vpu resulting in CD4
degradation in the ER [27].
The third class of E3 enzymes are the U-box proteins, which
contain a RING domain lacking the canonical cysteines for
Zn2þ coordination [28]. Nevertheless, U-box proteins can still
bind E2 enzymes as exempli¢ed by the recruitment of Ubc4/5
E2 enzymes to the Hsp90/Hsp70 co-chaperone CHIP [29]. In
this way, misfolded proteins that are recognized by Hsp90/
Hsp70 are proposed to be ubiquitylated and targeted for deg-
radation by the proteasome as reported for the cystic ¢brosis
transmembrane conductance regulator (CFTR) [30].
Fig. 1. A schematic view of the regulatory functions of the ubiquitin system in membrane protein transport. Proteasome-mediated ERAD is in-
volved in protein quality control of newly synthesized proteins via Ubc6 and -7 degradation. Rsp5 and SCFLTrCP are involved in (partial) deg-
radation of ER membrane proteins. At the Golgi complex the combination of Rsp5^Bul1 can direct Gap1 directly into the degradation route.
Endocytosis of ENaC via Nedd4 and GHR is regulated by the ubiquitin system, while the combination Nedd4/Tsg101 is involved in virus bud-
ding from the cell surface. A crucial step in downregulation of growth factor receptors and other regulatory membrane proteins is at the endo-
some, where the ubiquitin interacting motif containing protein Hrs/Vps27p, the deubiquitinase Doa4p and the ESCRTs co-operate to direct
them to the multivesicular bodies (MVB) and lysosomes (L) for degradation. The speci¢city of the selection process is probably provided by
E3 ligases, as is reported for the EGFR and c-Cbl.
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Proteins with a lysine 48-linked polyubiquitin tag are e⁄-
ciently recognized by the 26S proteasome and degraded. The
26S proteasome is a large (V2.5 MDa) multisubunit cytosolic
protease composed of a 20S catalytic core particle, which is
capped on both sides by a 19S regulatory multimeric complex
(reviewed in [31,32]). Proteasome inhibitors bind to the cata-
lytically active threonine residue of the L-subunits in the inner
rings [33,34]. The 19S cap complex is structurally divided into
an eight subunit ‘lid’ and a ‘base’, consisting of three non-
ATPase subunits and six homologous ATPases, presumably
involved in unfolding and translocating the substrate into the
20S catalytic chamber [35].
Mostly, the substrates are hydrolyzed into 8^11 amino-acid-
long peptides, Occasionally, limited-processing yields new bio-
logical active polypeptides, e.g. the transcription factors Spt23
and Mga2 arise from their membrane-anchored precursor
proteins by proteasome-dependent cleavage, probably via
hairpin intermediates [15]. Another well-studied example is
the generation of the p50 subunit of the nuclear factor
(NF)-UB transcription factor from its p105 precursor [36]. In
this case, a glycine-rich region prevents complete degradation
of p105 [37]. Strikingly, a glycine^alanine repeat prevents pro-
teasome degradation of the Epstein^Barr virus nuclear anti-
gen 1 (EBNA1) [38]. Since this precludes the presentation of
EBNA1 antigenic peptides by major histocompatibility com-
plex (MHC) molecules, EBNA1 escapes the immune system.
2. Ubiquitylation in membrane protein tra⁄c
As a major regulatory system of the cytosol and the nu-
cleus, it is not unexpected that the ubiquitin system is involved
in the tra⁄cking of a variety of membrane proteins at several
intracellular locations. An important functional parameter of
membrane proteins is their residence time at the cell surface.
The number of speci¢c proteins at the cell surface is within
certain limits regulated by their expression (gene expression,
mRNA stability, translation rate). However, once a mem-
brane protein, bound for the cell surface, has been synthesized
and translocated into the lumen of the ER, its presence and
abundance at the cell surface depends on a variety of factors,
which di¡er for each individual protein: time and e⁄ciency of
multimerization and ER quality control, transport rate from
ER to plasma membrane, rate of uptake via endocytosis, sus-
ceptibility to cell surface proteolysis, recycling e⁄ciency in the
endocytic route, and ¢nally, sorting e⁄ciency into lysosomes.
The major control points are depicted in Fig. 1.
The ¢rst controlling organel in the life of a membrane pro-
tein is the ER. In general, misfolded proteins are recognized in
the ER by a mechanism involving ER chaperones such as
calnexin and Bip (Kar2p in yeast), translocated to the cytosol
via the Sec61 translocon, polyubiquitylated and degraded by
the 26S proteasome [39]. This quality control mechanism is
referred to as ERAD and ensures that only correctly folded
and/or assembled proteins reach their ¢nal destinations in the
cell. Known examples of membrane proteins, whose number
at the cell surface is controlled by ER-based sorting mecha-
nisms, are CFTR [40] and the erythropoietin receptor (EpoR)
[41].
At the TGN, ubiquitylation determines the routing of the
yeast GAP1 and TAT2 tryptophan permease [42]. Depending
on nutrient conditions, these permeases are polyubiquitylated
and subsequently directed from the TGN to the vacuole (the
yeast equivalent of the mammalian lysosome) without emerg-
ing at the plasma membrane.
Clathrin-mediated endocytosis is a major factor in cell sur-
face residence time of membrane protein. In yeast, the K-fac-
tor (Ste2p) and a-factor (Ste3p) receptor, uracil (Fur4p), mal-
tose (Mal61p) and general amino acid (Gap1p) permease, and
the ABC-transporter Ste6p are ubiquitylated either constitu-
tively or in response to ligand binding (reviewed in [43]). In
mammalian cells, the GHR, epidermal growth factor receptor
(EGFR), platelet-derived growth factor receptor (PDGFR),
Met receptor and the epithelial sodium channel ENaC are
also targets of the ubiquitin system. In most cases, these pro-
teins are not degraded by the proteasome but, following ubiq-
uitylation, internalized and transported to the vacuole/lyso-
some (reviewed in [66]).
Many of the yeast proteins are monoubiquitylated or
tagged with a short lysine 63-linked polyubiquitin chain [43].
In fact, a single ubiquitin molecule appears to be su⁄cient to
induce internalization, since in-frame fusion of ubiquitin to
the stable plasma membrane protein Pma1 and Ste2p stimu-
lates their endocytosis [44]. Despite the lack of classical di-
leucine or tyrosine-based internalization motifs that can me-
diate the recruitment to coated membranes, the three-dimen-
sional structure of folded ubiquitin reveals an internalization
signal composed of two surface patches surrounding the crit-
ical residues phenylalanine-4 and isoleucine-44 [45]. Thus,
ubiquitin might bind adapter complexes directly. Recently,
another indication for the involvement of ubiquitylation and
the endocytosis machinery has been reported. Adapter pro-
teins of the endocytosis machinery such as eps15(R), and
epsins possess a ubiquitin-interacting motif (UIM), not only
involved in ubiquitin recognition but also in monoubiquityla-
tion of the proteins themselves [46,47]. Eps15 monoubiquity-
lation is also observed upon stimulation of mammalian cells
with EGF and is important for the activity of the endocytosis
machinery [48]. Because Eps15 can interact with clathrin
adapter proteins, it is conceivable that endocytosis of a cell
surface protein lacking a classical internalization motif can be
induced by its monoubiquitylation. Whether polyubiquity-
lated proteins use a similar pathway remains to be deter-
mined. Internalization of the G protein-coupled L2-adrenergic
receptor (L2AR) is also regulated via the ubiquitin system.
Activation of L2AR results in the recruitment of L-arrestin,
an adapter that can interact with clathrin. Although L2AR is
ubiquitylated, it is the ubiquitylation of L-arrestin by the
RING E3 Mdm2 that is essential for the internalization of
the complex [49]. It is conceivable that the ubiquitin moieties
on L-arrestin mediate the linkage to the endocytosis machin-
ery [50].
Following internalization, membrane proteins are delivered
to endosomes. Here, proteins, destined for degradation in the
vacuole/lysosome, are incorporated into the inward budding
vesicles (in later stages these structures are designated multi-
vesicular bodies MVBs), whereas others recycle back to the
plasma membrane via recycling endosomes [51]. The involve-
ment of the ubiquitin system in the sorting into internal
vesicles has been demonstrated in several ways. In response
to EGF, the EGFR is ubiquitylated by the RING E3 c-Cbl,
incorporated into internal vesicles of the MVB and degraded
in lysosomes [52,53]. Oncogenic Cbl mutants that lack ubiq-
uitin ligase activity, cause the recycling of the activated EGFR
back to the plasma membrane, and prolong EGFR signalling
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[54]. The yeast vacuolar carboxypeptidase S is monoubiquity-
lated on a single lysine residue and its mutation to arginine
prevents sorting into MVB vesicles [55]. Recognition of the
ubiquitylated proteins is mediated by ESCRT-1 (endosomal
sorting complex required for transport), a 350-kDa protein
complex consisting of Vps23p, Vps28p, and Vps37p. Vps23p
contains a UBC-like domain that resembles the UBC domain
of E2 enzymes but lacks the active site cysteine. This domain
is essential for binding of ubiquitylated substrates and sorting
into the internal vesicles [55]. The mammalian homolog of
Vps23p is a protein encoded by the tumor susceptibility
gene 101 (Tsg101) [56] and mutations in Tsg101 result in
tumorigenesis presumably due to recycling of receptors, as
seen for oncogenic Cbl mutants. Recently, mammalian hepa-
tocyte growth factor-regulated tyrosine kinase substrate (Hrs)
has been demonstrated to mediate sorting of ubiquitylated
substrates to the lysosome [51,57]. Like eps15 and epsins,
Hrs and its yeast homolog Vps27p contain a UIM that medi-
ates the binding to ubiquitin [46]. Because Vps27p is not a
component of the ESCRT-1 complex, it might function in
recruiting ubiquitylated cargo into the bi-layered structures
and MVB vesicles [51]. Another important factor in this sort-
ing process is Vps4, an ATPase of the AAA protein family
that appears to utilize the energy derived from ATP hydrolysis
to disassemble endosome-associated Vps complexes and there-
by allow multiple rounds of sorting [58]. Genetic studies in-
dicate that removal of ubiquitin moieties is necessary for com-
pletion of the sorting at the MVBs [59]. The DUB Doa4p
removes ubiquitin from cargo molecules and, in this way,
rescues ubiquitin molecules from degradation and restores
cellular ubiquitin homeostasis.
Recently, Tsg101 appeared to be essential for Hiv-1 and
Ebola virus budding from the cell surface [60^62]. Short pep-
tide motifs in the Hiv-1 Gag late domain and Ebola virus
matrix proteins recruit Tsg101 to sites of particle assembly
and a short, EbVp40-derived Tsg101-binding peptide se-
quence (PTAP) can functionally substitute for the Hiv-1
Gag late domain. This ¢nding reveals functional homology
between the process of inward vesicle budding as in MVBs
and virus budding at the cell surface. Morphological studies
have clearly illustrated that both Vps4 and Tsg101 are in-
volved in the ¢nal step of virus release. To explain the nature
of Tsg101 as a tumor suppressor, it would mean that a last
step in MVB vesicle budding is still reversible, as a defective
Tsg101 increases the number of growth factor receptors avail-
able for signalling [63].
Together, the ubiquitin system appears to regulate the
transport/sorting of many membrane proteins both in the bio-
synthetic, endocytic pathway, and in virus budding. Monou-
biquitylation and/or alternative linked polyubiquitin chains
might be a common theme. More importantly, regulation of
the tra⁄cking of membrane proteins is highly speci¢c due to
the versatility of E3 enzymes involved.
3. Growth hormone receptor (GHR) function, controlled by the
ubiquitin system
The number of GHRs per cell are regulated and this feature
plays a major role in the growth hormone (GH) responsive-
ness of the body. The availability of membrane proteins at the
cell surface can be regulated at di¡erent locations within the
cell : (1) The amount of protein synthesized in the ER is
largely controlled by gene transcription. In addition, the ER
quality control system regulates the exiting of properly folded
proteins from the ER. (2) In the TGN, proteins can either be
diverted directly to the lysosomes or be transported to the cell
surface. (3) At the plasma membrane, the endocytic machin-
ery can select proteins for endocytosis via clathrin-coated pits
or proteins may be subject to proteolysis, resulting in shed-
ding of the extracellular domain (ECD). (4) In endosomes,
internalized proteins either recycle back to the plasma mem-
brane or are targeted to the lysosome for degradation. At
each of these cellular locations the ubiquitin^proteasome
pathway can speci¢cally regulate protein levels via di¡erent
mechanisms. In transfected Chinese hamster lung cells,
GHR availability is determined by three factors: endocytosis
(75%), shedding (10%), and other undetermined mechanisms
(15%) [64]. Thus, the number of GHRs at the cell surface is
mainly regulated by the ubiquitin^proteasome pathway.
Three features render the GHR unique compared to other
receptors, signalling from the cell surface: (i) Endocytosis of
the GHR is constitutive. This means that its residence time at
the cell surface does not depend on the presence of ligand;
upon arrival at the cell surface from the ER/Golgi complex, it
is recruited into coated vesicles (like cargo receptors such as
the low-density lipoprotein (LDL) receptor) and transported
to lysosomes for degradation (unlike cargo receptors, which
release their cargo in endosomes, and immediately return to
the plasma membrane for the next round of endocytosis).
(ii) Endocytosis of the GHR depends on an active ubiquitin
system. We assume that this fact determines the average res-
idence time at the cell surface. There is evidence from many
clinical studies that in stress conditions the number of GHRs
is decreased, due to rapid endocytosis [65].
Thus, the ubiquitin system is a key regulator of GHR in-
ternalization. Both genetic and molecular experiments show
that GHR molecules accumulate at the plasma membrane if
the ubiquitin system is inhibited [66]. Moreover, GHR ubiq-
uitylation coincides with its recruitment into clathrin-coated
pits [67]. Strikingly, ubiquitylation of the GHR itself is not
required because replacement of all lysine residues by argi-
nines in the GHR cytosolic tail does not inhibit internaliza-
tion [68]. In our studies, we have identi¢ed the target of the
ubiquitin system in the GHR cytosolic tail as a 10 amino-acid-
long sequence, DSWVEFIELD, designated as the UbE motif
for ubiquitin-dependent endocytosis [68]. This motif is also
required for recruiting the GHR into the MVBs for lysosomal
degradation [51,69]. Besides the ubiquitin-conjugating system,
the 26S proteasome is involved in GHR downregulation. Pro-
teasome inhibitors prevent both internalization of the GHR
and endosome-to-lysosome transport [69,70]. The inhibitory
e¡ect is lost when the GHR is truncated beyond amino acid
369, suggesting that either the GHR or an associated protein
must be degraded by the proteasome before internalization
can occur [51,70]. Using a truncated receptor, it has been
demonstrated that proteasome inhibitors force the GHR
into recycling mode comparable to the tra⁄cking route of
cargo receptors. [51,69]. From these data, it is clear that the
ubiquitin^proteasome system regulates the turnover of the
GHR in two distinct events: internalization from the plasma
membrane and transport from endosomes to lysosomes. There
is a remarkable di¡erence between the involvement of the
ubiquitin system in GHR tra⁄cking and of other membrane
proteins: in most, if not all, systems reported, the activity of
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the ubiquitin system is preceded by protein phosphorylation.
For Ste2p and most permeases in yeast, phosphorylation of
serine or threonine is required before the E3 Rsp5 can initiate
their uptake [71,72]. In mammalian cells, uptake of ENaC
requires serine phosphorylation before the WW domain of
Nedd4 can bind to the tetrameric sodium channel (Fig. 1).
Degradation via the RING motif SCFLTrCP E3 requires pre-
vious phosphorylation as documented for NFUB, L-catenin,
Hiv-1 protein vpu, cyclins, myo-D, while c-Cbl stimulates
degradation of tyrosine kinase receptors only if their kinase
domain is active. As the signal transduction pathway of GHR
(via Jak2) is not involved in ubiquitin system-dependent en-
docytosis [73], and no other phosphorylation has ever been
observed, it is likely that in this case the ubiquitin system acts
directly on the GHR, raising the third unique point: (iii) The
ubiquitin system acts as primary regulator in GHR tra⁄cking.
Until now only the interaction p53^Mdm2 seems to be a
direct protein^protein interaction, independent of phosphory-
lation, implicating that the concentrations of these proteins in
cytosol and/or nucleus is a major factor in controlling cellular
life and death. Whether availability of GHRs at the cell sur-
face is subjected to the same kind of mechanism remains to be
elucidated.
4. GHR dimerization and ubiquitylation, a functional
connection
To be functional, most proteins occur as complexes. Com-
plex formation of membrane proteins can either be structural
or part of functional regulation. In general, structural com-
plex formation is part of the maturation process and takes
place in the ER. Functional complex formation often occurs
at the place of action; e.g. ligand binding might induce signal-
ling receptors to dimerize. Based on structural studies, GH-
induced dimerization of the GHR has long been the accepted
model for activation [74]. According to this model, GH-in-
duced dimerization of the GHR brings two Jak2 molecules
in close proximity, thereby facilitating trans-phosphorylation
of tyrosine residues in the kinase domain of the paired Jak2
[75]. Subsequently, these activated Jak2 molecules phosphor-
ylate tyrosine residues of the GHR and signalling molecules.
In general, PY residues serve as docking sites for proteins with
Src homology 2 or phosphotyrosine binding domains. How-
ever, from a mechanistical point of view, there are several
advantages in an alternative mechanism in which GH acti-
vates a preformed GHR dimer. It could considerably increase
signalling rate and lower the signalling threshold of GH con-
centration in the circulation. Recently, we obtained evidence
in favor of this alternative activation mechanism [76]. GHRs
form dimers immediately after their synthesis in the ER, and
these dimeric receptors continue to the cell surface. We used
sucrose velocity gradient centrifugation combined with short
pulse-labelling to show that indeed complex formation is ER-
located. The ER probably o¡ers the best environment due to
the high concentration of chaperones and of GHR precursor
polypeptides as multiple GHRs are inserted in close proximity
into the ER membrane by GHR mRNA-programmed poly-
ribosomes. Which ER chaperones play a role in dimerization
remains to be determined. Previously, Ross and colleagues
have shown that the number of binding sites for GH increases
upon incubation with a monoclonal antibody directed against
GHR subdomain 2, presumably by preventing dimer forma-
tion [77]. A similar increase was observed when the monova-
lent GH antagonist B2036 was used. They also suggested that
the antagonist binds to a preformed dimer in the absence of
the monoclonal antibody. Consistent with this ¢nding, cross-
linking of either B2036 or GH to the GHR revealed a similar-
sized complex consisting of a single GH and two GHR mol-
ecules [64].
Ligand-independent oligomerization has been reported for
various membrane proteins. In Table 1 the features of a se-
lected number of membrane receptors are collected. Pre-
formed dimers of the EpoR [78], the EGFR [79] and the
MT1R and MT2R [80], are activated through a ligand-in-
duced conformational change. Interestingly, in many cases
the transmembrane domain (TMD) is su⁄cient for di- or
oligomerization. Dimerization of glycophorin A (GpA) is cur-
rently one of the best-characterized examples. GpA is the
most abundant sialoglycoprotein in human erythrocyte mem-
branes and the formation of non-covalent SDS-stable dimers
facilitated these studies considerably. In the GpA TMD a di-
merization motif L75IXXGVXXGVXXT87 (L, leucine; I,
isoleucine; X, any amino acid; G, glycine; V, valine; T, threo-
nine) has been identi¢ed [81]. Nuclear magnetic resonance
spectroscopy con¢rmed this by positioning the speci¢c resi-
dues at the site of interaction [82]. The right-handed parallel
TMD K-helices cross at an angle of 340‡ and form a supercoil
with a closely packed interface, e.g. a ridges-into-grooves
structure. The GXXXG motif is the core of the dimerization
interface as the glycines stabilize the structure through Van
der Waals interactions with residues on the opposite helix [83]
and their mutation to alanine a¡ects dimerization the most
Table 1
Ligand-independent oligomerization of selected membrane proteins
Protein Function Type of oligomerization Interact. domain Reference
GHR metabol regulation homo-dimer TMD [76]
EpoR growth control homo-dimer TMD [78]
LeptinR metabol regulation homo-dimer n.d. [93]
EGFR (ErbB1) growth control homo/hetero-dimer TMD [79]
ErbB2 growth control homo/hetero-dimer TMD [94]
MHC class II antigen presentation hetero-dimer TMD [95]
TGFL type I and II R growth control homo-di-/hetero-tetramer n.d. [96]
MT1R or MT2R G-coupled receptor homo-/hetero-dimer n.d. [80]
TCRK and CD3N immune response hetero-oligomer TMD [97]
TNF p60 and p80 R cytokine receptor homo-trimer ECD [98]
GpA struct. prot. erythrocyte homo-dimer TMD [99]
EPO, erythropoietin; TGF, transforming growth factor; MT1R melatonin receptor 1; MT2R, melatonin receptor 2; TCR, T cell receptor;
TNF, tumor necrosis factor; n.d., not determined.
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[84]. Genetic and statistical data suggest that the GXXXG
motif is a common framework for TMD helix^helix interac-
tions [85]. The GpA TMD is a transferable dimerization unit
that can dimerize and thereby activate the bacterial ToxR
transcription activator [86] or induce transcytosis of the poly-
meric immunoglobulin receptor from basolateral to the apical
membrane [87].
The ligand-independent dimerization of the GHR is not just
an advantage for signal transduction, it appears also a con-
dition for ubiquitin system-dependent endocytosis of this re-
ceptor [76]. We showed that monomeric GHRs were internal-
ized rapidly and independent of an active ubiquitin
conjugation system using the Chinese hamster lung cell line
(CH-ts20) with a temperature-sensitive ubiquitin activating
enzyme. The underlying mechanism for the di¡erent mode
of internalization of monomeric and dimeric receptors is still
unclear. Apparently, the ubiquitylation machinery only recog-
nizes dimeric receptors. Alternatively, the ubiquitin^protea-
some system may be required to degrade a protein that asso-
ciates with and prevents the endocytosis of dimeric GHRs. To
our knowledge, no other membrane protein has been de-
scribed which is controlled by the ubiquitin system in a con-
formational-dependent fashion.
5. Mechanism of ligand-independent dimerization
How is dimerization achieved in the ER? For GHR, a role
for the cytoplasmic domain is unlikely because elimination of
97% of the cytoplasmic domain does not a¡ect the heterodi-
merization of the truncated GHR with full length GHR ([88]
and J.G., unpublished results). An increasing number of mem-
brane proteins has been reported to be mediated via their
TMD) [89]. We investigated this possibility by mutating single
and multiple amino acids in the TMD to alanine residues. In
addition, the GHR TMD was replaced by heterologous
TMDs known for their e¡ect on protein dimerization. Be-
cause none of the mutations disrupted GHR dimerization,
we conclude that the GHR TMD lacks speci¢c interaction
capacity. A role for amino acids in the membrane-proximal
subdomain 2 of the ECD has been proposed based on crys-
tallographic data [74]. Surprisingly, also mutations of these
amino acids did not a¡ect dimerization. Possibly, the single
mutations are not su⁄cient to disturb the extensive interac-
tion between the GHRs. In contrast, replacement of the com-
plete GHR ECD with a part of the LDL receptor-related
protein resulted in monomeric chimers [76]. Most likely, the
ECD is only required for the initial contact between the
GHRs, because protease-digestion of the ECD of cell sur-
face-localized (already dimerized) GHRs does not disrupt di-
merization of the membrane-bound remnant proteins. Once
brought into close contact, dimerization is probably main-
tained via the weakly interacting TMDs.
The mechanism of GHR dimerization di¡ers from that of
the homologous EpoR. The EpoR TMD is su⁄cient to medi-
ate ligand-independent dimer formation [90]. The EpoR
TMDs interact strongly, in contrast to that of GHR and
prolactin receptor (PrlR) [90]. Interestingly, there is only lim-
ited interaction between EpoR ECDs, whereas both GHR [74]
and PrlR ECDs [91] appear to interact extensively. Therefore,
EpoR dimerization requires a strong interaction between the
TMDs, whereas GHR and probably PrlR use their ECD
rather than TMD to induce dimerization.
6. Initiation of signal transduction
Although the GHR dimerizes in the absence of GH, signal
transduction pathways are only activated upon GH binding.
The activation upon GH binding most likely involves a con-
formational change of the GHR, which results in the activa-
tion of Jak2 tyrosine kinase at the cytoplasmic side. Muta-
tions of amino acids of subdomain 2 prevent this GH-induced
structural reorganization and yield signalling-de¢cient GHR
mutants. Because GH binds the GHRs sequentially [92], the
presence of preformed dimers o¡ers an advantage for rapid
signalling as no time is lost for recruiting a second GHR. This
would be especially advantageous in cells with low GHR lev-
els.
7. Concluding remarks
The number of functional GHRs at the cell surface can now
be understood in terms of a balance between synthesis and
degradation. Both processes add their special features: func-
tionality is only achieved if the receptors appear as dimers at
the cell surface, and only dimers obtain a special ticket to be
endocytosed by the ubiquitin system. This procedure warrants
that the number of receptors can be tightly and swiftly regu-
lated upon changed in the metabolic status of the cell ; it also
excludes non-dimerized receptors from taking part in the sig-
nalling process. These features render the GHR unique, and
the rationale is important to understand its role as a regulator
of cellular metabolism. Although many aspects of the molec-
ular mechanism of GHR downregulation have been estab-
lished, the precise mechanisms by which the link with the
ubiquitin^proteasome system is achieved remain to be re-
solved. Future work will need to establish the relative impor-
tance of the conformational changes inducing the Jak2 acti-
vation and signal transduction. It will also be crucial to obtain
structural information on a range of di¡erent GHR constructs
to see how £exible the domain structures are, as well as estab-
lishing the precise location and density of the interacting do-
mains to enable dimerization. In addition, it will be necessary
to establish which ER chaperones are involved.
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